What the data shows
The recent diagnoses of twins Emma and Bartosz Nelson with Spinal Muscular Atrophy (SMA) have raised significant concerns regarding the screening processes for this debilitating condition in the UK. The question at the forefront is: how can early detection of SMA improve the lives of affected children? The answer lies in the advancements in newborn screening and the potential for life-changing treatments.
Emma and Bartosz, who both have SMA type 1, the most severe form of the disease, were diagnosed at different times—Bartosz in 2021 and Emma in 2024. Their late diagnoses have likely resulted in lifelong mobility issues, a fate that could have been mitigated with earlier detection. In fact, it is estimated that 33 babies in the UK each year may require a wheelchair due to late diagnosis of SMA.
Spinal Muscular Atrophy is a genetic disorder that affects motor neurons in the spinal cord, leading to muscle weakness and atrophy. The Scottish government has taken a proactive step by announcing that all babies will be screened for SMA as part of the NHS newborn blood spot test. This initiative is crucial, as the UK currently lags behind 46 other countries, including the US and much of Europe, where newborn SMA screening is already in place.
Emma and Bartosz received the gene therapy Zolgensma through the NHS, a treatment that has shown promise in halting the progression of SMA and potentially eradicating the disease if administered early enough. Their parents, Jesy Nelson, Paola, and Rhys Davie, have expressed their gratitude for the treatment, emphasizing the joy they feel when they witness their children becoming stronger. Rhys stated, “Any moment like that when we can see she’s become stronger is incredible – we just feel so much gratitude and joy.”
However, the emotional toll of late diagnosis is evident. Paola reflected on the overwhelming feelings experienced at the beginning of their journey, stating, “I’m sorry you’re going through this. I remember how overwhelming it felt at the beginning.” This sentiment underscores the need for better awareness and support for families navigating similar challenges.
As the UK prepares for the projected rollout of SMA screening in England by 2031, the urgency for immediate action is clear. The current situation highlights the importance of advocacy and awareness surrounding SMA and the critical role of early detection in improving outcomes for affected children.
While the future of SMA screening in the UK looks promising, uncertainties remain about the implementation timeline and the extent of support available for families. As the community rallies around the Nelson family, the hope is that their story will inspire change and lead to a more proactive approach to newborn health screening across the nation.